WeLeader Biomedical Co

WeLeader Biomedical Co ROIC

The Return on Invested Capital (ROIC) of WeLeader Biomedical Co (7713.TWO) as of Oct 24, 2026 is 11.93 %. In the previous year, Return on Invested Capital (ROIC) was 13.03 % — a change of -8.45% (lower).

ROIC

11.93 %

YoY

-8.45%

Last updated:

Return on Invested Capital (ROIC) of WeLeader Biomedical Co is 2025 11.93 % . Return on Invested Capital (ROIC) of WeLeader Biomedical Co was 2024 13.03 % . It decreases by -8.45% lower compared to the previous year.

The WeLeader Biomedical Co ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2020
6.90 TWD
Jan 1, 2021
28.13 TWD
Jan 1, 2022
16.78 TWD
Jan 1, 2023
13.91 TWD
Jan 1, 2024
13.03 TWD
Jan 1, 2025
11.93 TWD
The WeLeader Biomedical Co ROIC history
YEARROICYoY
11.93 %-8.45%
13.03 %-6.33%
13.91 %-17.11%
16.78 %-40.34%
28.13 %+307.79%
6.90 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

WeLeader Biomedical Co Stock analysis

What does WeLeader Biomedical Co do? WeLeader Biomedical Co Ltd generates revenue through the agency and trading of in vitro diagnostic instruments and reagent-related products, primarily serving domestic markets. The company provides distribution, after-sales, and maintenance services for laboratory reagents, consumables, instruments, and equipment, alongside construction planning for medical testing laboratories. Additional services include equipment procurement, operational coaching, human resources training, and digital medical examination platforms. Domestic clients purchase these integrated solutions for healthcare facilities and laboratories. The firm's product portfolio focuses on medical testing-related services, including operational coaching and digital platform solutions, which are sold to healthcare institutions requiring comprehensive laboratory support. Distribution of in vitro diagnostic instruments and reagents forms a core revenue stream, supported by ancillary services like equipment procurement and site construction planning. These offerings target domestic healthcare providers seeking efficient laboratory management solutions. WeLeader Biomedical Co Ltd's business model combines product sales with service delivery, emphasizing domestic market penetration. The company's revenue is derived from both the sale of diagnostic instruments and reagents and the provision of specialized services such as operational coaching and digital platform access. Healthcare institutions and laboratories are the primary buyers of these integrated offerings, leveraging the company's expertise in laboratory construction and equipment maintenance. WeLeader Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about WeLeader Biomedical Co stock

Return on Invested Capital (ROIC) of WeLeader Biomedical Co is 11.93 % in 2025.

Return on Invested Capital (ROIC) of WeLeader Biomedical Co changed from 13.03 % to 11.93 %, representing a -8.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) WeLeader Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s WeLeader Biomedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — WeLeader Biomedical Co

All Key Metrics — WeLeader Biomedical Co